DNA Therapeutics is a private clinical-stage biopharmaceutical company dedicated to the R&D of life-saving therapeutics to combat treatment-resistant cancers. It is based on a paradigm-shift technology, DNA repair signal jamming, also named DNA (signal interfering DNA), which deals with DNA repair pathways as a global target.

Our vision

The progression of cancer is associated with the deregulations in multiple pathways responsible for controlling cell growth and differentiation including DNA repair processes. The Discovery and development of new drugs at DNA Therapeutics are based on the knowledge of DNA damage sensing, signaling, and repair. This is an original approach to improve the efficacy of conventional therapies in the treatment of resistant cancers.

Our mission

Developing cutting-edge technologies and innovative medicines that will significantly improve the treatment of cancer by inhibiting DNA repair-related processes, overcoming cancer resistance, thus addressing highly unmet medical needs.

Our strategy

Exploiting the utmost from DNA technology, a pathway targeting, and a mechanism-oriented approach, and adding progressively other anticancer weapons to enrich its armamentarium/product pipeline through a business-driven drug development in order to establish strategic partnership(s) for late-stage development, marketing, and commercialization.

Our ambition

  • Entering the biopharmaceutical arena thanks to a proprietary cutting-edged DNA repair signal jamming technology and innovative medicines with strong translational research support from the renowned public research institutions;
  • Bringing this paradigm-shift approach to success by validating the DNA repair signal jamming concept in the clinic and by leveraging its financial consequences;
  • Becoming a ¬†successful Virtually Integrated Pharmaceutical Company (VIPCo) with a well balanced and sustained pipeline;
  • Playing a key role in the advancement of therapies against cancer and other biologically related diseases in the future.